**BACKGROUND**

Lymphocyte effects of the BEMPEG + NIVO combination enrolled in PIVOT-02 (n=65, Mean+SD) were assessed by Key MEL Inclusion Criteria:

- **Key Inclusion Criteria:** Patients with measurable disease per RECIST v1.1
  - 41 MEL patients enrolled and received at least one dose of BEMPEG + NIVO
  - Measurable disease per RECIST v1.1
  - ECOG 0-1
  - Unresectable locally advanced or metastatic disease
  - Cisplatin-eligible who have refused standard of care inhibitors (CPIs)

**DOSE ESCALATION**

- **SOLID TUMORS**
  - BEMPEG + NIVO 240 mg q2w
  - BEMPEG + NIVO 360 mg q3w

**RESULTS**

- **2.5 4.5 5 2 1**

**Rapid Activation of the Immune System Was Observed with BEMPEG and NIVO**

**RESULTS**

- **2.5 4.5 5 2 1**

**Patients with Ongoing Response 16/20 (80%)**

**CONCLUSIONS**

- **2.5 4.5 5 2 1**

**DISCUSSION**

- **2.5 4.5 5 2 1**